Following a lackluster first quarter for small biotechs, the pharmaceutical industry is witnessing a surge in tuck-in deals. Ventyx, with upcoming Phase II Parkinson’s disease results, struck a deal with Sanofi granting the pharma right of first negotiation (ROFN) on an acquisition. This agreement, driven by a shared interest in novel central nervous system therapies, […]
Tag: Lilly
Innovative ANGPTL3-Targeting Therapies for High Cholesterol
Exciting developments in the biotech industry are paving the way for new treatments targeting high cholesterol. Recent studies presented at the American College of Cardiology Scientific Session have shown promising results for ANGPTL3-targeting drugs developed by Eli Lilly and Jiangsu Hengrui Pharmaceuticals. Eli Lilly’s solbinsiran, a small interfering RNA therapy, demonstrated significant reductions in apolipoprotein […]
Lilly’s $870M Deal for Long-Acting GLP-1 Obesity Drugs
Lilly’s Mounjaro and Zepbound, weekly injectable drugs targeting GIP and GLP-1, lead in the obesity and diabetes market with over $6 billion in sales. To maintain its position, Lilly is developing new injectables and oral options. Despite progress, competition from less frequent dosing therapies poses a challenge. Read more from biospace.com
